Navigation Links
More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
Date:12/3/2008

ct #1005: Saturday, December 6, 2008; 5:30 PM PST)
  • Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan-Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies (ASH Abstract #958: Saturday, December 6, 2008; 5:30 PM PST)
  • A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma (ASH Abstract #2774: Sunday, December 7, 2008; 6:00 PM PST)
  • Other highlights of data to be presented at SABCS include:

    RAD001

    • Multicenter Phase I clinical trial of daily and weekly RAD001 (everolimus) in combination with vinorelbine and trastuzumab in HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab (SABCSAbstract #406: Friday, December 12, 2008; 7:00 - 9:00 AM CST)
    • RAD001 (everolimus) in combination with weekly paclitaxel and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab: a multicenter Phase I clinical trial (SABCSAbstract #3119: Friday, December 12, 2008; 5:00 - 7:00 PM CST)

    About Gleevec

    Gleevec(R) (imatinib mesylate) tablets are indicated for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in the chronic phase. Follow-up is limited to 5 years. Gleevec is also indicated for patients with Ph+ CML in blast crisis (BC), accelerated phase (AP), or in the chronic phase (CP) after failure of interferon-alpha therapy.

    Fetal harm can occur when administered to a pregnant woman; therefore, women of childbearing potential should be advised to not b
    '/>"/>

    SOURCE Novartis Pharmaceuticals Corporation
    Copyright©2008 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

    Related medicine technology :

    1. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
    2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
    3. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
    4. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
    5. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
    6. Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects
    7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
    8. New Conflict of Interest Violations Revealed at California Stem Cell Institute
    9. St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia
    10. Protein Tomography(TM) Reveals Molecular Mode of Action of Humax-EGFr Published in PNAS
    11. Imaging Results From the ADAGIO-LIPIDS Reveal That Effects of Rimonabant on Cardiometabolic Risk Profile Include Loss of Visceral Fat and Mobilization of Liver Fat
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/3/2015)... -- Landauer, Inc. (NYSE: LDR ), a recognized leader ... medical physics services and high quality medical consumable accessories, ... fiscal third quarter 2015 after the market close on ... will also host a conference call for investors on ... (10:00 a.m. Eastern Time). Investors may access the live ...
    (Date:8/3/2015)... and MINNEAPOLIS , ... BSX ) has become a significant shareholder and ... representative for Preventice Solutions for cardiology-related diagnostic and ... an important strategic milestone for Preventice Solutions," said ... Strategy Officer, co CEO, Preventice Solutions.  "We are ...
    (Date:8/3/2015)... 3, 2015 Diplomat Pharmacy, Inc. (NYSE: DPLO ... for the quarter ended June 30, 2015. All comparisons, unless ... Second Quarter 2015 Highlights include: ... $266 million , Total prescriptions dispensed of 234,000, an ... 5.5% , Adjusted EBITDA of $22.7 million, an increase ...
    Breaking Medicine Technology:Landauer, Inc. Announces Date And Time For Announcement Of Fiscal Third Quarter 2015 Results And Conference Call 2Boston Scientific Announces Equity Investment And Sales Cooperation Agreement With Preventice Solutions 2Diplomat Announces 2nd Quarter 2015 Financial Results 2Diplomat Announces 2nd Quarter 2015 Financial Results 3Diplomat Announces 2nd Quarter 2015 Financial Results 4Diplomat Announces 2nd Quarter 2015 Financial Results 5Diplomat Announces 2nd Quarter 2015 Financial Results 6Diplomat Announces 2nd Quarter 2015 Financial Results 7Diplomat Announces 2nd Quarter 2015 Financial Results 8Diplomat Announces 2nd Quarter 2015 Financial Results 9Diplomat Announces 2nd Quarter 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 11Diplomat Announces 2nd Quarter 2015 Financial Results 12Diplomat Announces 2nd Quarter 2015 Financial Results 13Diplomat Announces 2nd Quarter 2015 Financial Results 14Diplomat Announces 2nd Quarter 2015 Financial Results 15Diplomat Announces 2nd Quarter 2015 Financial Results 16Diplomat Announces 2nd Quarter 2015 Financial Results 17Diplomat Announces 2nd Quarter 2015 Financial Results 18
    ... Jennerex,Inc. (San Francisco, CA and Ottawa, Ontario), and ... of the first five patients in a,Phase 2 primary ... JX-594. No significant toxicities were reported, and enrollment of,patients ... The Phase 2 trial involves treatment of patients ...
    ... Pulmo BioTech Inc. has completed a dual listing. The ... (symbol PBO) in addition to the OTC BB (OTC ... role in the future development and financing of the ... the United States and Canada" - Garry McCann, CEO ...
    Cached Medicine Technology:Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 2Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 3Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 4Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse 2Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse 3
    (Date:8/4/2015)... ... August 04, 2015 , ... ... analysis for executives and technology professionals in healthcare and technology markets, today announced ... the Department of Defense’s recently-announced Electronic Health Record (EHR) decision. The DOD related ...
    (Date:8/3/2015)... ... August 04, 2015 , ... Approved ... extensive line up of live courses for the month of August. , Physical ... individually or by purchasing a Physical Therapy Flex package. Flex packages allow ...
    (Date:8/3/2015)... ... August 03, 2015 , ... ... Putnam counties. As a family owned and operated business, Zeiter’s Septic has ... They are a leader in septic installations because of their continued training and ...
    (Date:8/3/2015)... ... August 03, 2015 , ... Since 1978, the number ... according to a new publication released today by the AAMC (Association of American Medical ... graduates over the past three decades, the number of black male applicants to medical ...
    (Date:8/3/2015)... ... ... According to an opinion piece published July 28 by the Washington Post, the ... weight loss may not be accurate. While this system may work for some people, the ... – based both on the individual and at what point that person is in their ...
    Breaking Medicine News(10 mins):Health News:Coverage of DOD’s EHR Decision Reinforces Healthcare IT News’ Leadership 2Health News:Elite Online CE Provider Announces Schedule of Live Courses For Florida Physical Therapy Continuing Education 2Health News:Elite Online CE Provider Announces Schedule of Live Courses For Florida Physical Therapy Continuing Education 3Health News:Zeiter’s Septics Performs Affordable Septic Installations Throughout Livingston & Putnam Counties Effective Immediately 2Health News:Zeiter’s Septics Performs Affordable Septic Installations Throughout Livingston & Putnam Counties Effective Immediately 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 2Health News:New Publication Focuses on the Decline of Black Males in Medicine 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 4Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2
    ... of Internal Medicine journal, Obese or overweight Chinese individuals ... developing tuberculosis than those at a normal weight. ... undernutrition in both developed and developing countries. In addition, ... a wide range of chronic degenerative conditions, notably, diabetes ...
    ... University of Washington shows that the work intended for ... economy . ,The research was conducted by a ... Hagopian, professor in the School of Public Health and ... Initiative; and Sally Weatherford, finance and administration director of ...
    ... guitarist Kevin Eubanks have won the 'World's Sexiest Vegetarians' title at ... new to the title, for she won the tag in 2005 ... for NBC's 'Tonight Show' band leader Eubanks, who bagged votes due ... for the 49-year-old and 'bring honour' to the show. ...
    ... researchers identify cost-effective treatment for drug-resistant typhoid. Researchers ... may be more effective at treating typhoid fever ... Organisation. ,Enteric fever, of which typhoid fever ... affecting the developing world, where sanitary conditions remain poor. ...
    ... have found that umbilical cord blood might safely preserve insulin ... ,The study was conducted by a team of ... Florida. ,As part of the study, researchers identified ... their umbilical cord blood at birth, and gave seven patients ...
    ... study published in the Journal of the National Cancer ... cancers is increasing, but this finding is likely ... Deirdre Cronin-Fenton, Ph.D., of Aarhus University Hospital in Denmark, ... Md., found that the increase in some early stage ...
    Cached Medicine News:Health News:Obesity is Related to Lower Tuberculosis Risk 2Health News:Global Health Enriching the States Economy 2Health News:Gatifloxacin Very Effective for Typhoid Treatment 2
    ... ring pessary, available in nine ... support, is a very common ... second degree prolapse. The Ring ... used on an accompanying cystocele. ...
    The Capio CL Transvaginal Suture Capturing Device allows for a transvaginal suture fixation to Cooper's Ligament for sling procedures...
    ... SPARC™ Sling System utilizes a suprapubic ... incontinence due to urethral hypermobility and/or ... two curved, narrow-diameter needles and a ... suture that allows for intra-operative tension ...
    ... technology marries with the well-researched ... sling, for exceptional resultsby design. ... and host, reduces the potential ... or erosion and provides secure ...
    Medicine Products: